Promising News in Melanoma From ASCO 2017
As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a po...
Author: patientpower
Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts
Promising News in Melanoma From Annual Meeting 2017
As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a po...
Author: patientpower
Added: 06/30/2017 (Source: Oncology Tube)
Source: Oncology Tube - July 1, 2017 Category: Cancer & Oncology Source Type: podcasts
KEYNOTE-029 Results: Pembrolizumab + Low-Dose Ipilimumab in Metastatic Melanoma Patients
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his first presentation, which focused on the results of the KEYNOTE-029 trial at the 2017 ASCO Annual Meeting in Chicago, IL. <br /><br />Pembro...
Author: ASCO2017
Added: 06/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Nivolumab + Anti-LAG-3 Antibody in Metastatic Melanoma
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his second presentation, which focused on the use of nivolumab plus an anti-LAG 3 antibody for the treatment of metastatic melanoma at t...
Author: ASCO2017
Added: 06/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Impact of Studies on Metastatic Melanoma ResearchWhats Next?
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses what the next steps are for these two clinical trials and the impact of these studies on future clinical practice and research in metast...
Author: ASCO2017
Added: 06/13/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 13, 2017 Category: Cancer & Oncology Source Type: podcasts
Can NKTR-214 Work For Other Cancers?
Adi Diab, MD of MD Anderson Cancer Center discusses a common question he's asked, regarding the use of NKTR-214 for not only renal cell carcinoma and melanoma, but for other cancers as well. This was ...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: Effect of IL-2 Cytokine Immune Agonist (NKTR-214)
Adi Diab, MD of MD Anderson Cancer Center gives an overview of his abstracts, which focus on the use of NKTR-214 for treatment of patients with renal cell carcinoma and melanoma. This was recorded at ...
Author: ASCO2017
Added: 06/12/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2017 Category: Cancer & Oncology Source Type: podcasts
PodMed – Week of June 12, 2017
This week’s topics include patient monitoring of cancer symptoms and survival, negative impact of alcohol consumption, lymph node dissection in melanoma, and significance of small aneurysms in brain. 0:32 Patient monitoring of cancer symptoms and survival 1:34 Reported to nurse 2:39 Advanced melanoma and lymph node dissection 3:35 Half had dissection and survival observed 4:46 […] (Source: Johns Hopkins Medicine Weekly Health News)
Source: Johns Hopkins Medicine Weekly Health News - June 9, 2017 Category: Consumer Health News Authors: Elizabeth Tracey Johns Hopkins Medicine Tags: Alcohol And Drug Abuse All Podcasts Cancer Neurology And Neurosurgery PodMed Source Type: podcasts
Impact of Combination of Talimogene and Ipilimumab on Clinical Practice
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Efficacy of FDA-Approved Combination Regimens in Melanoma Patients with Brain Metastases
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the most exciting and interesting presentations coming out of ASCO 2017, which include three oral presentations, focusing on...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Common Questions Asked Concerning the Study
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center talks of the common questions most physicians ask regarding his study on talimogene laherparepvec and ipilimumab in melanoma. This was...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: Phase II Study of Talimogene Laherparepvec and Ipilimumab in Melanoma
Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center gives an overview of his presentation which focused on the use of talimogene laherparepvec and ipilimumab versus ipilimumab alone in m...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
Management of Brain Metastases in Melanoma: An Overview of COMBI-MB and CheckMate 204
Manmeet S. Ahluwalia, MD of Cleveland Clinic discusses three abstracts presented at ASCO 2017, highlighting the management of brain metastases in melanoma. This was recorded at the 2017 ASCO Annual Me...
Author: ASCO2017
Added: 06/05/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2017 Category: Cancer & Oncology Source Type: podcasts
ENCORE 601: ENT in combination with PEMBRO in Advanced Melanoma Patients
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. gives an overview of his presentation, Abstract #9529 ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO...
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2017 Category: Cancer & Oncology Source Type: podcasts
2017 Treatment Trends for Melanoma
Briggs Morrison MD, CEO of Syndax Pharmaceuticals, Inc. discusses the treatment trends in 2017 for advanced melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Author: ASCO2017
Added: 06/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - June 3, 2017 Category: Cancer & Oncology Source Type: podcasts
